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Antitumour Activity and Retinotoxicity of 
Ethyldeshydroxy-sparsomycin in Mice
H.P. Hofs, D J.Th. Wagener, D. De Vos, H.C.J. Ottenheijm, H J. Winkens, 
P.H.M. Bovee and WJ. De Grip
The colony formation in agar of human tumour xenografts was used as a test system to study the cytostatic 
activity of ethyldeshydroxy-sparsomycin (EdSm) at the cellular level. EdSm was additionally studied in vivo in 
human tumour xenografts and murine tumour models. EdSm showed a clear dose-response effect in vitro. At 
continuous exposure with 0.01 fxg/ml, 2 out of 11 of the tumours responded (a gastric and a small cell lung 
carcinoma). At 0.1 (i/ml EdSm, the tumour response was 5/11 tumours and at 1 jjig/ml the compound was active 
in all tumours. The maximal tolerable doses of EdSm in vivo have been determined in non-tumour bearing CDFj 
mice. In the intraperitoneally (i.p.) given multiple dose schedules the respective LD10 doses indicated that the 
tolerable cumulative dose increases when lower doses are given more frequently. This also enhances the 
antitumour activity in L1210 leukaemia to 172% T/C. On the other hand, continuous infusion strongly diminished 
the tolerable dose as well as the antitumour activity. EdSm was also active against i.p. inoculated P388 leukaemia 
(150% T/C), B16 melanoma (156% T/C), and RC carcinoma (197% T/C), and the subcutaneously (s.c.) inoculated 
L1210 (139% T/C) and RC (138% T/C). Absence of tumour responses was found in the following s.c. implanted 
murine tumours: M5076 sarcoma, osteosarcomas C22LR and CP369, and the LL carcinoma, as well as in the 
human tumour xenografts: LXFG 529, a non-small cell lung carcinoma; GXF 251, a gastric carcinoma; and FMa, 
an ovary carcinoma. Possible long-range retinotoxic effects of EdSm were investigated in tumour-bearing mice, 
cured after surviving treatment with l d 50 doses of EdSm, by assaying the protein biosynthetic capacity of the 
retina by assaying the ocular rhodopsin and opsin levels as parameters. In none of these cases could a significant 
reduction in either opsin or rhodopsin levels be measured and no changes were seen histologically.
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INTRODUCTION
T he  natural product sparsomycin (Sm) is an antibiotic pro­
duced by Streptomyces sparsogenes and Streptomyces cuspidosporus. 
It was discovered in 1962 by Owen and associates [1] and 
characterised by Argoudelis and Herr in 1962 [2]. Antitumour 
activity was observed towards P388 leukaemia only [3]. A clinical 
phase I study with Sm (NSC-59729) was initiated in 1964 by
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Close and McFarlane., using a daily schedule for 10-14 days [4]. 
This study was discontinued because 2 out of 5 patients reported 
blurred vision» probably caused by degeneration of the retinal 
pigment epithelium [4, 5],
Despite these disappointing phase I results there is still 
interest in Sm and its derivatives have attracted our attention. 
Firsdy, an important aspect is that their mode of action differs 
from classical antitumour agents. These Sm compounds are 
potent inhibitors of protein synthesis by blocking the ribosomal 
peptidyl transferase centre [6- 11]. Because of this different mode 
of action s Sm and several derivatives were used in combination 
chemotherapy studies and were shown to enhance the anti- 
tumour activity of cisplatin [12-14]. The structure-activity 
relationship of Sm derivatives has been explored and several 
were found to have a therapeutic index broader than that of Sm  
itself. Overall, ethyldeshydroxy-sparsomycin (EdSm) showed 
the best biological activities [15, 16]. Secondly, the use of high  
daily doses o f cytotoxic drugs in phase I studies has been  
abandoned nowadays because of the high risk of accumulation 
and toxicity. Finally, intensive histopathological and biochemi­
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cal analysis of animal models failed to show retinal toxicity of 
Sm and one analogue, even at repeated toxic doses [17, 18]. 
Moreover, the synthesis of suitable analogues might overcome 
the putative ocular toxicity. Therefore, we have extensively 
studied the antitumour activity and retinotoxicity of EdSm. In 
this report the results are summarised and discussed,
MATERIALS AND METHODS
Drugs
EdSm was synthesised at the department of Organic Chemis­
try of the University of Nijmegen, The,Netherlands [17], and 
was acquired in a lyophilised form. The drug was dissolved in 
phosphate buffered saline (pH 7.4) and stored at 4°C in dark 
flasks. Solutions with the required drug concentration were 
prepared just before administration by dilution with isotonic 
NaCl.
Maximal tolerable dose
*
The acute toxicity of EdSm has been determined in normal 
CD2F1 mice. The 50% and 10% lethal doses (l d 50 and LD10, 
respectively) were determined after administration on various 
routes and schedules. For bolus injections we used five dose 
levels and six mice per dose level. For continuous administration 
of EdSm to normal and tumour-bearing mice, we used Alzet 
osmotic minipumps 1003 D and 1007 D (Alza, Palo Alto, 
California, U .S.A .). The 1003 D minipump has a volume of 
100 1^ and a flow capacity of 1.06 ± 0.05 fxl/h continuously over 
3 days. The 1007 D  minipump also has a volume of 100 |u.l, but 
a flow capacity of 0.5 jxl/h continuously over 7 days. These 
minipumps were filled with an EdSm solution in isotonic NaCl. 
Pumps were implanted intraperitoneally (i.p.) or subcutaneously 
(s.c.) under ether anaesthesia. Three mice were used per dose 
level in osmotic minipumps.
In vitro xenografts
Experiments with human tumour xenografts were performed 
by Dr H .H . Fiebig, Department of Internal Medicine, Division  
of Haematology-Oncology, University of Freiburg, D-7800 
Freiburg, Germany. Human tumours, established in serial 
passage in nude mice, as described by Fiebig and colleagues
[19], were used. A single-cell suspension of the solid human 
tumours was obtained by mechanical disaggregation with scis­
sors and subsequent incubation with enzymes, as described by 
Fiebig and colleagues [20]. The two-layer soft-agar culture 
system introduced by Hamburger and Salmon [21] was modified 
as described by Fiebig and colleagues [19]. In the colony assay, 
EdSm was applied by continuous exposure until the end of the 
experiment. Three dose levels were studied in triplicate and in 
each experiment six untreated cultures were used as controls. 5- 
Fluouracil (100 ^xg/ml, continuous exposure) was added as a 
positive reference drug. A compound was considered active if  it 
reduced colony formation to 30% or less of the control value.
Antitumour activity
Three human tumours were used to study the antitumour 
activity of EdSm in vivo: a non-small cell lung carcinoma (LXFG  
529), a gastric carcinoma (GXF 251) (both studies were tested 
by Dr H .H . Fiebig), and an ovary carcinoma (FMa), (tested by 
Dr E. Boven, Free University Hospital, Amsterdam, The 
Netherlands). The murine leukaemia tumours P388 and L1210 
and the solid tumours B16 melanoma and RC renal cell carci­
noma were obtained from G. Atassi, Brussels. They were 
passaged and maintained in animals as recommended by the
NCI. The experiments with the osteosarcomas C22LR and L L , 
the Lewis Lung carcinoma and M5076 sarcoma were performed 
at the Radiobiological Institute T N O  in Rijswijk as reported by 
Zylicz and associates [18]. T he osteosarcoma CP368 was tested 
at CIVO-TNO, Zeist, The Netherlands, by Dr P. Lelieveld. In 
the treatment of subcutaneously growing human and murine 
tumours EdSm was administered to tumour-bearing animals, 
with tumour sizes between 25 and 50 mm3, at a dose level o f 5 
and 10 mg/kg on days 1, 5 and 9. Animals were randomised 
before treatment.
S  tudies on retinotoxic effects
CD2F1 mice were obtained from Charles River Breeding 
Laboratories, Inc. Male mice weighing between 18 and 22 g were 
inoculated intraperitoneally with 105 L1210 cells. Acceptable 
median control survival times range from 8-11 days for L1210
1.p. tumour. EdSm and cisplatin were administered i.p. at 
various doses on days 1, 5 and 9 after tumour implantation. Eye 
toxicity was investigated in tumour-bearing animals which were 
recorded as cures after drug treatment [22].
Rhodopsin assay. Animals were dark-adapted for 24 h to 
ensure maximal regeneration o f rod visual pigment (opsin to 
rhodopsin). All procedures were carried out in dim red light 
(> 6 1 0  nm). After pentobarbital anaesthesia the eyes were extir­
pated, placed in light-tight containers and directly frozen at 
-80°C . The animals were sacrificed afterwards. Extraction 
and assay of rhodopsin have been described previously [23]. 
Rhodopsin was measured by difference spectroscopy and the 
rhodopsin concentration was calculated from the difference in 
absorbance at 500 nm before and after illumination, using a 
molar absorbance coefficient o f 403 000.
Opsin assay. For quantitative determination of opsin, the 
earlier described enzyme-linked immunosorbent assay (ELISA) 
was used [24, 25],
Histopathology. Eyes were fixed in Bouin solution and embed­
ded in paraffin according to standard procedures [26]. Sections 
of 5 fxm were stained with haematoxylin and eosin, and sub­
sequently analysed microscopically.
RESULTS
The cytostatic activity o f EdSm was studied in 11 human 
tumour xenografts in vitro in doses ranging from 0.01  to 1.0 jxgI 
ml (0.0278-2.78 fxM) given by continuous exposure (Table 1). 
A clear dosenresponse relationship was established. At the dose 
of 0.01 fig/ml 2 out of 11 human tumours ( 18%) were sensitive, at 
0.1 jxg/ml this was 45% and at 1.0 pig/ml all tumours responded, 
suggesting that if  an EdSm concentration o f about 2.8 piM can 
be maintained at the cellular tumour level over a longer period 
in vivo , this tumour will respond positively to EdSm treatment.
Before determining the antitumour activity of EdSm in differ­
ent animal tumour models, we investigated the acute toxicity in 
normal CD2F1 mice. The 50% and 10% lethal doses (l d 50 and 
l d 103 respectively) were determined after i.p . EdSm adminis­
tration on various schedules; the results are summarised in Table
2. For single dose treatment the intravenous (i.v.) route was 
more tolerable than the i.p . route; the l d 10 values are 48.8 and 
24.9 mg/kg, respectively. This difference disappeared upon 
daily administration. Additionally, these data indicate that 
EdSm is better tolerated when it is given more frequently at 
lower doses. Daily i.p. administration for 9 days results in a LD10
EJC 31:9-G
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Table 1. In vitro effect o fE d S m  on 11 human tumour cells derived 
from xenografts in nude mice expressed as the number o f
responseslthe number tested
Drug concentration (jig/ml)
Tumour Passage No. 0.01 0.1 1
CXF 609 8 + +
GXF 251 15 + + + + + + + +
GXF 97 23 --- + -t- + +
LXFA 526 15 --- + + + 4* ■+■
LXFG 529 6 + + + + 4- +
LXFK 605 10 --- >— + + +
LXFK 650 12 + + + + + +
LXFL 1029 4 ---------- — + + +
MAXF 401 12 ---------- + + + + +
TXF 423 11 ---------- - — . + + +
XF 299 15 ---------- + + + +
Sensitive* 2/11 5/11 11/11
Tumours were considered to be responsive if the colony count was 
30% of the control at continuous exposure.
CXF, colon cancer xenograft; GXF, gastrix; LXF, lung; A, adeno, G, 
large cell* K, small cell; MAXF, mammary; TXF, testicular; XF, 
miscellaneous cancer xenograft.
* Sensitive = + +  and + + + ; T/C >  50% -  — ; 30% <  T/C 
< 50% = +; 10% ^  T/C s  30% = + + ;T/C < 10% = + + + .
Table 2 . Tolerable doses o fE d S m  in mice after administration on
various schedules
Schedule Route LD10 l d 50 m R
SD i .p . 24.9 30.0 11.8 0.959
D l, 5, 9 i .p . 37.2 44.1 13.0 0.993
Dl-9* i .p . 54.0 72.0
Cl i .p . 2.96 4.48 5.3 0.998
SD i.v. 48.8 57.7 13.1 0.995
Dl-7* i .v . 48.3
SD, single dose; D l, 5, 9, treatment on day 1, 5 and 9; D l-7  and D l-9, 
daily treatment for 7 or 9 days, respectively; Cl, continuous infusion 
during 3 days, using osmotic minipumps (1003D); i.p.> intraperitoneal; 
i.v., intravenous; ld 10, cumulative doses in mg/kg that results in 10% 
lethality; ld50, cumulative doses in mg/kg that results in 50% lethality; 
m, the coefficient signifying the shape of the dose-effect curve for the 
agent used; R, the linear correlation coefficient of the dose-effect curves. 
* Results presented by Zylicz and associates [18].
of 54 mg/kg. However, EdSm is less tolerable when given as a 
continuous infusion, resultingin a l d 10 dose of 2.96 mg/kg over 
3 days.
Based on these l d 10 values the anti tumour activity of EdSm 
was determined in animal tumour models. As presented in Table
3, all i.p . inoculated murine tumours (L1210, P388, B16 and 
RC) responded positively to daily i.p. EdSm administration 
(%T/C >  135%), The L1210 model was used to investigate the 
effect o f different treatment schedules. W hen EdSm was given 
in three doses ( D l ,  5, 9)3 the anti tumour activity against L 1210 
was still comparable to that observed upon daily administration 
(158% and 172%, respectively). On the other hand, continuous 
infusion i.p. for 3 or 7 days lowered the activity to 130 and 120%, 
respectively, and no antitumour response was seen when these 
minimpumps were placed s.c. , despite the increased EdSm dose
Table 3. Summary o f the antitumour activity o fE d S m  in 8 murine
tumours and 3 human tumour xenografts in vivo
Tumour Site Schedule Route Dose* Responsef Ref.
L1210 IP D l-9 i.p. 55 172 [18]
L1210 IP DI, 5, 9 i.p. 15 158 [16]
L1210 IP CI D1-3 i.p. 1 130
L1210 IP CI D 1-3 s.c. 2 100
L1210 IP CI D l-7 i.p. 2 120
L1210 IP CI D l-7 s.c. 2 100
L1210 SC D l-7 i.v. 48 139 [18]
P388 IP Dl-9 i.p. 55 150 [18]
B16 IP Dl-7 i.p. 35 156 [38]
RC IP Dl-9 i.p. 37 197 [18]
RC SC Dl-7 i.v. 42 138 [18]
M5076 SC Dl-9 i.p. 55 100 [18]
C22LR SC D2-10 i.p. 55 100 [18]
CP369 SC DI, 5, 9 i.p. 15 100
LL SC DI, 5 ,9 i.p. 22.5 100 [18]
LXFK 529 SC D l, 5 i.p. 20 100
GXF 251 SC D l, 5, 9 i.p. 30 100
FMa SC DI, 5, 9 i.p. 30 100
For explanations see also Table 2. i.p., intraperitoneally; i.v., 
intravenously; s.c., subcutaneously.
* Cumulative dose in mg/kg; f  Median survival time in % of treated 
over control (% T/C).
of 2 mg/kg. From the s.c. implanted tumours appreciable T/C 
values (>  135%) were only obtained with L I210 and RC. N o  
significant antitumour response was measured in the M5076, 
C22LR., CP369 and LL tumour models. The two human tumour 
xenografts most sensitive to EdSm in vitro; i.e. the large cell lung 
cancer LXFG 529 and the gastric carcinoma GXF 251, as well 
as the ovary carcinoma FMa were tested in vivo. EdSm at a dose 
of 5 or 10 mg/kg} given i.p. on days 1, 5 (LXFG 529) or 1, 5, 9 
(GXF 251 and FMa), did not exert any antineoplastic effect in  
any of these tumours.
Retinopathy
Toxic effects of EdSm on the protein biosynthetic capacity of 
the retina were assessed by assaying the rhodopsin and opsin 
levels in tumour-bearing mice, cured after treatment with doses 
of EdSm which were toxic for normal standards ( ld 50). The 
photoreceptor cell-RPE (rednal pigment epithelium) complex 
accomplishes a high turnover rate of visual pigment (ca. 10% 
per day) and in order to maintain a constant level the photorecep­
tor cell has a high biosynthetic capacity for the protein opsin 
(5-10 pmol/106 cells per day) [27]. Perturbations like inhibition 
of this process will, therefore, rapidly lead to a reduction in 
ocular opsin content, and may eventually effect an almost 
complete loss in visual pigment protein. For conversion of the 
apoprotein opsin into the photoactive pigment rhodopsin, the 
photoreceptor cell relies on the production of the required 
chromophore, 11-cis retinal, by the enzymatic machinery of the 
retinal pigment epithelium [28]. Selective inhibition of this 
process could result in impaired ocular opsin levels and reduced 
rhodopsin levels. In order to incorporate possible additive effects 
due to tumour- and other disease-related pathogenicity, the 
toxicity of EdSm was investigated in tumour-bearing mice which 
survived on relatively high doses ofEdSm or Sm, in combination 
with cisplatin, which at high doses can also cause retinotoxicity
[29]. In none of these cases could a significant reduction in either
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opsin or rhodopsin levels be measured (Table 4). N one o f the 
eyes of mice treated with cisplatin and EdSm showed histological 
changes.
DISCUSSION
The toxicity of Sm analogues in mice is related to their 
lipophilicity; it decreases with increasing lipophilic character
[17]. Therefore, EdSm could be administered at much higher 
doses than Sm, e.g. ld 50 of 8 mg/kg for EdSm compared 
with 0.26 mg/kg for Sm for the i.p. schedule D l-9 .  Osmotic 
minipumps have been very useful in the study of the effects of 
continuous drug treatment [30-34]. Chronic administration of 
EdSm using 100 jxl osmotic minipumps over 3 days turned out 
to be less tolerable ( ld 10 =  2.96 mg/kg) and less therapeutic than 
repeated bolus injections. Thus, the therapeutic window of 
EdSm treatment when given chronically seems to be low.
Previous studies have demonstrated that exposure o f Chinese 
hamster fibroblast cells to Sm for 1 h inhibits over 99% of their 
protein synthetic capacity, but is lethal for only 25% of these 
cells, due to the fact that after removal of the drug the cells 
recovered their protein synthesising ability. This reversibility 
disappeared after longer periods of incubadon [35]. Similarly, 
chronic EdSm treatment might cause an irreversible protein 
imbalance due to permanent inhibition of protein synthesis, 
which would enhance its toxicity to normal tissues. W hen lower 
doses are given at frequent intervals the cumulative tolerable 
dose for EdSm increases and the antitumour response is 
improved. Under those conditions, appreciable antitumour 
activity for EdSm (>  135%) is obtained when the tumour site as 
well as the drug treatment is i.p ., and in two s.c. implanted 
tumours (L I210 and RC) when EdSm was given i.v . (139% 
and 138%, T/C respectively). Worth mentioning is that no 
antitumour activity of EdSm was noticed when the tumour was 
implanted s.c. and drug treatment was i.p . It is not clear yet 
whether this is due to the treatment schedule (D l, 5, 9 instead 
of D l-9 )  or mainly due to i.p. instead o f i.v, administration. 
The strongest antitumour responses were obtained upon daily 
EdSm administration, i.p. when the tumour was implanted i.p . 
and i.v. when the tumour was implanted s.c. From this we 
conclude that the application route of choice for EdSm in animal 
tumour models should implement i.p. administration for i.p. 
tumours and i.v. administration for s.c. tumours.
Table 4. Rhodopsin and opsin concentrations in eyes o f  C D 2F I  
mice, 6-8  months o f age, which were alive and tumour-free 100 days 
after combined treatment with cisplatin and E dSm  in the L 1210
tumour model
Treatment % Survivors *Rhodopsin/eye fOpsin/eye
Group I 33 0.64 ± 0.05 0.65 ± 0.06
Group II 67 0.66 ± 0.03 0.65 ± 0.03
Group III 60 0.67 ± 0.04 0.68 ± 0.02
Group IV 67 0.66 ± 0.02 0.68 ± 0.06
Group V 67 0.63 ± 0.05 0.61 ± 0.07
Control 0.71 ± 0.07
Mice from all these groups were histologically checked for degeneration 
of the neural retina and retina pigment epithelium.
Group I, cisplatin 4 mg/kg; group II, cisplatin 4 mg/kg and EdSm 
10 mg/kg; group III, cisplatin 3 mg/kg and EdSm 5 mg/kg; group IV, 
cisplatin 3 mg/kg and EdSm 10 mg/kg; group V, cisplatin 3 mg/kg and 
Sm 1.5 mg/kg [14, 22].
* Spectroscopy,« = 4 ± S .D .;f ELISA,n  ~ 4 ± S.D.
Under the auspices o f the National Cancer Institute (Bethesda, 
Maryland, U .S .A .) additional toxicological studies in rats and 
monkeys have been performed [36]. Retinotoxicity was assessed 
by electroretinography (ERG) and eye histology. Abnormal 
electroretinograms were only observed in moribund rats, prob­
ably due to their poor general condition. N o ERG changes were 
seen in monkeys. Histopathological changes were not detected 
in any animal. The plasma membrane o f reticulocytes is rather 
impermeable for Sm [37]. On the basis of these studies, the Sm- 
related retinopathy is suggestive of a poor general condition, and 
possibly o f inappropriate drug schedules. Since the first reports 
on retinal toxicity o f Sm preparations concern late-stage patients, 
to a large degree in cachectic condition [4, 5], we extended 
these analyses to tumour-bearing mice and included the more 
lipophilic Sm derivative EdSm, which will more easily cross the 
blood-re tin a barrier. N o evidence was found for any re tino toxic 
action of Sm or EdSm, either on a supracellular level (retinal 
morphology) or on a subcellular level (protein biosynthesis, 
intracellular and intercellular transport). These novel obser­
vations are fully in line with our previous results. W e have to 
conclude that Sm-derivatives are not re tino toxic.
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